Feature|Videos|December 10, 2024
Breaking barriers: EnzeneX™ to EnzeneX™ 2.0
Author(s)Enzene
Shilpa Gadgil, PhD (VP, Head of Process and Analytical Development, Head of CDMO Development) discusses Enzene's new technologies and the New Jersey site capabilities.
Shilpa Gadgil, PhD, from Enzene, discusses the company's Fully-Connected Continuous Manufacturing™ (FCCM™) platform and EnzeneX™ 2.0 for commercial biologics supply, as well as which large molecules have been successfully produced using the platforms. She also covers Enzene's new biologics site in New Jersey and the bottlenecks the company has overcome regarding transfer and scale-up.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
How the Wegovy Pill Approval Reshapes Solid Dosage Manufacturing Strategy
2
Innovation and Market Exclusivity in the EU
3
Harnessing Data and Secure Cloud Environments for Global Pharma Solutions
4
Orchestrating the Pharmaceutical Future: Living Decision Engines and AI Integration
5